A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients

• Status: Completed
• Trial end date: 2017-11-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to compare the development of new geographic atrophy in patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab or aflibercept over 24 months. Geographic atrophy is an advanced form of AMD that can result in the progressive and irreversible loss of visual function over time.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Aflibercept; Ranibizumab

Criteria

Inclusion criteria:

• Written informed consent.

Inclusion criteria specific to the study eye:

• Diagnosis of active subfoveal Choroidal Neovascularisation (CNV) secondary to wet Age-related Macular Degeneration (AMD);

• Best Corrected Visual Acuity (BCVA) score of 23 letters or more as measured by 3-metre Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts.

Exclusion criteria:

• Pregnant, nursing, or at risk of becoming pregnant during the study;

• Inability to comply with the study or follow-up procedures;

• Recent (3 months) stroke or myocardial infarction; uncontrolled hypertension; hypersensitivity to the study treatments or to fluorescein;

• In either eye: active periocular or ocular infection or inflammation; iris neovascularisation; uncontrolled or neovascular glaucoma; or one or more patch of geographic atrophy (GA) as specified in the protocol.

Exclusion criteria specific to the study eye:

• Prior or current treatment with anti-angiogenic drugs or corticosteroids;

• Other eye conditions as specified in the protocol;

• Any intraocular procedure carried out within 2 months before baseline or anticipated within 6 months following baseline.